Global Autoimmune Gastrointestinal Dysmotility Market Projected to Reach $2.3 Billion by 2029 at a CAGR of 5.9%
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What is the Projected CAGR for the Autoimmune Gastrointestinal Dysmotility Market Size from 2025 to 2034?
There has been significant growth in recent years in the autoimmune gastrointestinal dysmotility market size. This market is projected to expand from $1.73 billion in 2024 to $1.83 billion in 2025, experiencing a compound annual growth rate (CAGR) of 6.0%. The historic growth can be traced back to factors such as increasing ignorance about rare diseases, growth in underdeveloped diagnostic procedures, higher incidences of misdiagnosis with other gastrointestinal disorders, a rise in the shortage of targeted therapies, and escalating delays in research advancements.
In the forthcoming years, the autoimmune gastrointestinal dysmotility market is set to experience robust growth. The market size is projected to reach $2.30 billion in 2029, with a 5.9% compound annual growth rate (CAGR). Factors contributing to this growth during the predicted period include an increase in the prevalence of autoimmune diseases, enhancements in diagnostic methods, a rise in healthcare spending, heightened rare disease awareness, and improved education for clinicians. The forecasted period will also see key trends like advancements in diagnostic technology, breakthroughs in immunotherapy, progress in neurogastroenterology research, research into motility modulators, and customised treatment plans.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
What are the Fundamental Drivers and Innovations Shaping the Autoimmune Gastrointestinal Dysmotility Market?
The autoimmune gastrointestinal dysmotility market is projected to grow due to the increasing incidences of autoimmune disorders. Autoimmune diseases occur when the body’s immune system erroneously harms its healthy cells rather than safeguarding them from infections and foreign bodies. The increasing rate of these disorders is predominantly owing to the interplay between genetic vulnerability and environmental factors, which together disrupt the regulation of the immune system, making it more likely to harm its own tissues. Autoimmune gastrointestinal dysmotility aids in pinpointing and overseeing autoimmune disorders by uncovering immune-triggered damage to the enteric nervous system, thus linking gastrointestinal symptoms to systemic autoimmune reactions. For instance, a 2022 study by Versorgungsatlas.de surveyed 73,241,305 individuals, of which 6,304,340 had at least one autoimmune disease diagnosis, pointing to an observed prevalence rate of 8.61. Therefore, rising autoimmune disorder diagnoses are pushing the growth of the autoimmune gastrointestinal dysmotility market forward. The expanding concentration on personalized medicine which contributes to perfected treatments for individual autoimmune conditions, is acting as a catalyst for the market growth. Personalized medicine, a form of therapy distinctly tailored to a patient’s unique genetic attributes, lifestyle, and surroundings, is expected to drive the autoimmune gastrointestinal dysmotility market. Personalized medicine’s ascent is primarily due to developments in genomics, which permit exact identification of genetic variants, consequently enabling tailored treatments for individuals. In the realm of autoimmune gastrointestinal dysmotility treatment, personalized medicine enhances therapeutic efficiency and reduces side effects by adapting treatments to a person’s unique genetic profile and particular disease traits, thereby providing more precise solutions for managing complex gastrointestinal disorders. The U.S. Food and Drug Administration, in line with the Personalized Medicine Coalition’s report, approved 26 new personalized medicines in 2023, up from the 12 approved in 2022. Consequently, the growing emphasis on personalized medicine is fueling the growth of the autoimmune gastrointestinal dysmotility market.
How Is the Autoimmune Gastrointestinal Dysmotility Market Segmented?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
Which Regions Are Driving the Next Phase of the Autoimmune Gastrointestinal Dysmotility Market Growth?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Autoimmune Gastrointestinal Dysmotility Market?
Key corporations in the autoimmune gastrointestinal dysmotility market are strategically partnering up to deliver digital therapeutic solutions specially designed to manage such medical conditions. Collaborative strategies enhance patient care via a virtual-first approach, extensive healthcare teams, improved symptom management, increased access to necessary care, and cost efficiency for autoimmune gastrointestinal dysmotility. For example, in March 2022, Solera Health, a US digital health firm, collaborated with Oshi Health and Vivante Health, two other US digital health companies, to forward this cause. The partnership is intended to offer top-notch digital therapy solutions that aid in managing and treating autoimmune gastrointestinal dysmotility. The coordinated effort seeks to boost access to specialty care for patients and enhance the overall effectiveness of treatments for those suffering from gastrointestinal disorders.
View the full report here:
How Is the Autoimmune Gastrointestinal Dysmotility Market Defined and What Are Its Core Parameters?
Autoimmune gastrointestinal dysmotility (AGID) is a rare disorder where the immune system attacks the nerves controlling digestive tract movement. This disorder leads to slowed or abnormal motility, causing symptoms such as nausea, bloating, constipation, or intestinal blockage. Autoimmune gastrointestinal dysmotility (AGID) is often associated with autoimmune conditions or may occur as a paraneoplastic syndrome.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
